L1 Global Manager Pty Ltd purchased a new position in shares of Drugs Made In America Acquisition Corp. (NASDAQ:DMAA – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 200,000 shares of the company’s stock, valued at approximately $2,075,000. Drugs Made In America Acquisition makes up 1.4% of L1 Global Manager Pty Ltd’s investment portfolio, making the stock its 16th biggest position. L1 Global Manager Pty Ltd owned approximately 0.69% of Drugs Made In America Acquisition at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of the business. Wolverine Asset Management LLC boosted its position in Drugs Made In America Acquisition by 4.7% during the fourth quarter. Wolverine Asset Management LLC now owns 1,307,468 shares of the company’s stock worth $13,564,000 after purchasing an additional 58,340 shares in the last quarter. Mercuria Capital Strategies LLC purchased a new position in shares of Drugs Made In America Acquisition in the fourth quarter valued at approximately $7,511,000. Boothbay Fund Management LLC purchased a new position in shares of Drugs Made In America Acquisition in the second quarter valued at approximately $5,814,000. Radcliffe Capital Management L.P. lifted its position in shares of Drugs Made In America Acquisition by 316.7% in the third quarter. Radcliffe Capital Management L.P. now owns 528,100 shares of the company’s stock valued at $5,424,000 after acquiring an additional 401,378 shares in the last quarter. Finally, Context Capital Management LLC purchased a new position in shares of Drugs Made In America Acquisition in the third quarter valued at approximately $2,568,000.
Drugs Made In America Acquisition Price Performance
NASDAQ:DMAA opened at $10.61 on Friday. Drugs Made In America Acquisition Corp. has a one year low of $10.17 and a one year high of $10.62. The stock has a 50 day moving average price of $10.57 and a 200 day moving average price of $10.47.
Analysts Set New Price Targets
Separately, Weiss Ratings restated a “sell (d)” rating on shares of Drugs Made In America Acquisition in a research report on Friday, May 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.
View Our Latest Research Report on DMAA
About Drugs Made In America Acquisition
Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.
Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.
Featured Articles
- Five stocks we like better than Drugs Made In America Acquisition
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Receive News & Ratings for Drugs Made In America Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made In America Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
